REGENXBIO Inc.

Ownership Transactions Reported by 18 Insiders

Symbol
RGNX on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
9804 Medical Center Drive, Rockville, MD

Insiders trading volume in the past year

REGENXBIO Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Allan M. Fox Director $23.1M May 30, 2025
Kenneth T. Mills Director $3.85M -$163K -4.06% May 30, 2025
Curran Simpson Chief Executive Officer, Director $2.38M -$154K -6.08% Sep 29, 2025
Olivier Danos Chief Scientific Officer $1.83M Feb 1, 2025
Steve Pakola Chief Medical Officer $1.7M Feb 1, 2025
Patrick J. Christmas Chief Strategy & Legal Officer $1.24M Aug 1, 2025
Vittal Vasista Chief Financial Officer $927K Mar 19, 2024
Mitchell Chan Chief Financial Officer $482K Sep 1, 2025
Jennifer Zachary Director $176K May 30, 2025
Craig Malzahn Chief Technology Officer $157K Sep 1, 2025
Daniel Tasse Director $152K May 30, 2025
Alexandra Glucksmann Director $152K May 30, 2025
Jean Bennett Director $152K May 30, 2025
George V. Migausky Director $152K May 30, 2025
David C. Stump Director $152K May 30, 2025
Argeris N. Karabelas Director $152K May 30, 2025
Daniel Abdun-Nabi Director Jun 4, 2021
Luke M. Beshar Director Jun 4, 2021

Recent Insider Transactions by Companies or Individuals for REGENXBIO Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.